glp-1 agonists thyroid cancer Forest plot of receptor versus comparators on risk of GLP-1 Agonists: A Comprehensive Overview

Identical Pharmacy eligibility criteria to SGLT-2 inhibitor Empagliflozin, but funding is either or Some patient could benefit from both SGLT-2 inhibitor and GLP-1 agonists

J Diabetes Metab Disord 24 , 253 (2025)

Liu X, Zhang Y, Zheng S-Y, et al

Semaglutide at higher doses (2.4 mg weekly) has shown the most robust evidence for NASH resolution in clinical trials, achieving resolution in 59% of patients

Taken together, this real-world study shows that GLP-1RA is associated with a reduced risk of AF compared with other non-insulin glucose-lowering agents other than SGLT2i, suggesting that cardiovascular benefits of GLP-1RA use may extend to prevention for AF in patients with diabetes

Weight loss, weight maintenance, and improved cardiovascular risk factors after 2 years treatment with orlistat for obesity